Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the label of Ozempic.
The U.S. Food and Drug Administration (FDA) has approved Novo Nordisks (NYSE:NVO) Ozempic for reducing the risk of kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback